16 citations,
July 2021 in “Histopathology” New markers and pathways have been found in skin tumors, helping better understand and diagnose them.
10 citations,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
7 citations,
August 2017 in “PloS one” Key genes linked to hair growth and cancer were identified in hairless mice.
3 citations,
June 2023 in “Frontiers in medicine” Oxidative stress may contribute to hair loss in alopecia areata and antioxidants could potentially help as a treatment.
New treatments for vitiligo may focus on protecting melanocyte stem cells from stress and targeting specific pathways involved in the condition.
2 citations,
November 2023 in “Frontiers in microbiology” The health of the gut may be important in developing new ways to prevent, diagnose, and treat alopecia areata.
2 citations,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
2 citations,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
2 citations,
May 2017 in “InTech eBooks” Stem cells could improve hair growth and new treatments for baldness are being researched.
1 citations,
September 2020 in “Cochrane library (CD-ROM)” The analysis aims to identify the most effective and safest treatments for alopecia areata.
1 citations,
May 2017 in “InTech eBooks” Hair loss in Androgenetic alopecia (AGA) is due to altered cell sensitivity to hormones, not increased hormone levels. Hair growth periods shorten over time, causing hair to become thinner and shorter. This is linked to miscommunication between cell pathways in hair follicles. There's also a change in gene expression related to blood vessels and cell growth in balding hair follicles. The exact molecular causes of AGA are still unclear.
April 2024 in “Medical & clinical research” More research is needed to find the best long-term treatments for Alopecia Areata.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
October 2023 in “Frontiers in endocrinology” Effective PCOS treatments require targeting specific signaling pathways.
September 2023 in “Frontiers in medicine” The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.
February 2023 in “Research Square (Research Square)” Blocking IL-17 can reduce skin inflammation in a mouse model of pityriasis rubra pilaris.
August 2022 in “Revista de la Universidad Industrial de Santander/Salud UIS” Stress-related hair loss was reversed with a special medication.
July 2011 in “British Journal of Dermatology” Dermatologists give better information on pathology forms, hypersensitivity vasculitis is a common skin issue, misdiagnoses can occur, and various skin conditions are linked to loss of elastin or genetic factors.
176 citations,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
26 citations,
October 2016 in “Biomolecules & Therapeutics” 3-Deoxysappanchalcone helps human hair cells grow and stimulates hair growth in mice by affecting certain cell signaling pathways.
19 citations,
September 2019 in “EMBO molecular medicine” Blocking TSLP reduces skin inflammation and cell overgrowth in psoriasis.
9 citations,
July 2017 in “Journal of medical case reports” Ruxolitinib treatment may cause eyelash growth.
3 citations,
June 2022 in “Dermatology and therapy” A new botanical treatment improved hair growth and symptoms in lichen planopilaris patients.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
March 2024 in “Frontiers in genetics” Different types of fibroblasts play specific roles in wound healing and cancer, which could help improve treatments.
New insights into cell communication in psoriasis suggest innovative drug treatments.
November 2023 in “Frontiers in pharmacology” Drug repositioning offers hope for new, affordable treatments for a genetic skin disorder called ARCI.
9 citations,
January 2020 in “Skin appendage disorders” Hair loss from conditions like LPP and FFA can potentially be reversed with the right treatment.
38 citations,
January 2019 in “International Journal of Women's Dermatology” The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.